Member Info for Diversified

Already confirmed in a previous RNS that results will be released to market on Monday, expecting forward guidance for the remainder of 2021 and perhaps a revision to the projected £10m revenue.

These are not every day trades, we only need to look to the trading history to see that this type of transaction is infrequent at best and more importantly may signify the end of an exit for a particular shareholder.

Tomorrow might mark the beginning of a recovery as FOMO approaches through to the end of the month in anticipation of next weeks news.

- Approx 17% of total market cap backed by cash.

- China Resources is a game changing JV said to be non dilutive, increases capacity to meet ‘country’ contract demand in 18 month installed rollout from September.

- Question is, will the MHRA phase three breath test also validate the Covid waste water pathogen, as they are one of the same I would say it does. Therefore it becomes the enabler to contracts on both fronts.

My best guess

N - It certainly has a lot going for it, the chart TA looks ripe to rip.

I continue to read and learn, it would appear to me that the current shareholder register is frustrated by pace of disclosed progress. For me the institutions will arrive in significant numbers if all falls into place, and certainly if revenue for 2021 increases at a pace anywhere near to what some have suggested on here. All seems up for grabs.

It’s interesting that he made reference in June 2020 to a business model that he had used in a previous company of his that was able to increase turnover from 5/35m within two years by actively partnering with others which in turn reduced capex and took advantage of other companies distribution channels.

You can see the volume/capacity from the China Resources deal that would take the Wastewater monitoring arm to another level and allow for the widely touted deals in Europe as part of a wider expansion via an OEM. It’s first major deal would then prove to others it’s immediate value and would facilitate a rapid growth in deals.

It has taken me a while to get my head around what appears to be the commercialization roadmap, but it’s all their to be pieced together.

If this turns out to be anything like what I think it could, today’s market cap is simply ludicrous and presents a unique proposition.

Is anyone expecting an upwards revision to 2021 £10m revenue guidance on Monday?

I expect forward guidance to be revised based on likely progress with China Resources with a conservative caveat implying that this is dependent on completion of the deal.

I can’t see why the CEO would tweet about the chambers of commerce if Gerard and Linian LI were not confident of progress towards the 30th June implied target date.

I have no doubt that the recent placing has strengthened what is a predominately private shareholder register. Management and new institutions in the recent placing will be invested over a longer time frame.

Volume is by no means significant which in turn reduces liquidity and increases volatility. It will be newsflow that ultimately drives this share price.

Take advantage of the dips if you believe in the fundamentals. It may of taken some time to hit the commercial end of the newsflow that will reinvigorate interest, but I see no reason to disbelieve the imminent timetable.

Sorry, this was meant for DVRG. But this will have a direct bearing on this stock and they should both move in tandem

- 23rd June

General meeting results

- 28th June

Audited results and ‘forward guidance’.

- 30th June (imminent)

Mou update, signature and commercial guidance

- Imminent (as per comms from company)

Breath test

With additional information coming for all quarters of the business model during Q3, what drives the share price? Newsflow!

We are at the commercial end of proceedings, this is now Deepverge’s moment, and the market and its respective investors are not only fully aware of what is forthcoming, but that new shares are to be issued to those that committed with this in mind. Any affect on share price. I doubt it!

Imminent rerating and pick up in volume will keep us all on our toes! Enjoy!

- 23rd June

General meeting results

- 28th June

Audited results and ‘forward guidance’.

- 30th June (imminent)

Mou update, signature and commercial guidance

- Imminent (as per comms from company)

Breath test

With additional information coming for all quarters of the business model during Q3, what drives the share price? Newsflow!

We are at the commercial end of proceedings, this is now Deepverge’s moment, and the market and its respective investors are not only fully aware of what is forthcoming, but that new shares are to be issued to those that committed with this in mind. Any affect on share price. I doubt it!

Imminent rerating and pick up in volume will keep us all on our toes! Enjoy!

It is

This TPP may be helpful for the following possible scenarios:
? Generally, low-risk and low prevalence (<1%) settings, such as workplaces, schools and universities, where there is a high likelihood of repeat testing (e.g. everyday).
? At large-scale events where tests may need rapid deployment in high numbers to
identify positive cases (e.g. sports events, theatres).

Size of market phenomenal and game changing for the younger currently unvaccinated population.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/966283/Breath_TPP_Final_version_v1.0.pdf

It’s coming home LOL!

I promise I am not weird enough to stalk!!!

Based on the reported temperature being consistent with Beijing, and that not a single location in Europe shares the reported 34 degree Celsius he has referred to it’s possible to draw some conclusions. Especially when the reported statement below:

‘Joint Venture which are expected to be signed by 30 June 2021 with the JV becoming operational by 1 September 2021. ’

Business travel more likely than social IMO.

https://twitter.com/gjbrandon/status/1406318433701093377?s=21

If as suggested the MOU results in a listing on the Hong Kong exchange, it maybe of interest to some to know that the minimum required market cap for a listing on that exchange is approx £47m or $500m HK.

I honestly can’t understand why this company is so under the radar in terms of expectation in comparison to others.

- Mou/JV/Modern water

A complete under reaction in the share price to what can be a game changing outcome in its own right. Why has the market not reacted to this and rerated the stock in expectation of news that could come as soon as the 30th June. Referred to as a non dilutive and possible end point with a Hong Kong listing, implying a way to monetize an asset. With this and prospects inside and outside of Europe.

- Breath test

Results referred to as imminent, with high sensitivity and specificity like no other with results in seconds. It can transform our present environment in a number of attractive settings.

- skincare

Generating significant revenue on a major growth trajectory.

To have raised the money at a relatively low discount to market price and to be sitting within a strong technical pattern that could see a major breakout and momentum. I honestly can’t understand why this hasn’t already turned the markets head in a major way.

Between market makers at close to balance the books. A good day and an evident increase in interest.

Is well worth a read. It’s going to be a very busy 9 months with commercialization of no fewer than 3 products.

It’s worth noting that Belluscura has already filed for approval to be supplied through MediCare and expects clearance within 60 days. As the prospectus was published on the 24th May the very latest it could receive clearance is by the 22nd July and most likely sooner as it has already been filed prior to to publication as above and likely closer to the March FDA approval date.

Next month will see the launch of the first ‘pulse dose’, product, targeting a US $434m market. Followed by 2 further products that will be launched in November and January respectively, these will target the continuous flow market which is a US $2.745m market.

With further detail to follow on international clearances such as CE approval. We may also see a ‘private label’ agreement during the second half of this year and perhaps prior to next months launch with an unnamed party. This has specifically been referenced in relation to the product thar will launch next month.

With discussions ongoing with distributors and indicated orders of over 500 units for July’s launch, with a suggested but unconfirmed 25/35% margin and the promise of significant growth in both revenue and recruitment, the market won’t be able to ignore this for much longer IMO.

Oh shut up!!! LOL

*multiple patents